TickerFacts.

Twist Bioscience Corp (TWST): Cost of Revenue

Annual figures by period end, from SEC filings.

$185.57M
Year ended 2025-09-30
$207.41M
Trailing 12 months to 2026-06-30
+15.9%
3-year compound annual growth
+24.8%
5-year compound annual growth
2017-09-30: $24.02M2018-09-30: $32.19M2019-09-30: $47.43M2020-09-30: $61.41M2021-09-30: $80.62M2022-09-30: $119.33M2023-09-30: $155.38M2024-09-30: $179.62M2025-09-30: $185.57M$185.57M
2017-09-30 Cost of Revenue (USD) 2025-09-30
Period endedCost of RevenueChange YoYSource filing
2025-09-30$185.57M+3.3%2025-11-17, From 2024-10-01
2024-09-30$179.62M+15.6%2025-11-17, From 2023-10-01
2023-09-30$155.38M+30.2%2025-11-17, From 2022-10-01
2022-09-30$119.33M+48.0%2024-11-18, From 2021-10-01
2021-09-30$80.62M+31.3%2023-11-21, From 2020-10-01
2020-09-30$61.41M+29.5%2023-06-05, From 2019-10-01
2019-09-30$47.43M+47.3%2021-11-23, From 2018-10-01
2018-09-30$32.19M+34.0%2020-11-27, From 2017-10-01
2017-09-30$24.02Mn/a2019-12-13, From 2016-10-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Twist Bioscience Corp (TWST)2025-09-30$185.57M+3.3%
Immunocore Holdings plc (IMCR)2025-12-31$5.09M+86.3%
ADMA Biologics, Inc. (ADMA)2025-12-31$217.41M+5.1%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$71.36M-1.0%
Vericel Corp (VCEL)2025-12-31$70.66M+8.5%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$173.18M+85.7%
Repligen Corp (RGEN)2025-12-31$352.01M-2.2%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$70.0Kn/a
REGENXBIO Inc. (RGNX)2024-12-31$33.57M-9.8%

Compare TWST, IMCR, ADMA, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗